Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and CyclosporinDavid J. Curtis, Geoffrey R. Hill, John Stubbs et al.|New England Journal of Medicine|2025Cited by 52
Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in <i>NPM1</i> mutated or <i>KMT2A-</i>rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform TrialSun Loo, Andrew H. Wei, Adam Ivey et al.|Blood|2024Cited by 9